TNYA Tenaya Therapeutics Inc
501
$4.14
8.81%
| Watchers | 501 |
| 52-Wk Low | $1.66 |
| 52-Wk High | $8.09 |
| Market Cap | $356.47M |
| Volume | 331,015.00 |
| 52-Wk High | $8.09 |
| 52-Wk Low | $1.66 |
Tenaya Therapeutics (NASDAQ:TNYA) PT Lowered to $18.00 at Canaccord Genuity GroupTicker Report • 2 months ago
Tenaya Therapeutics (NASDAQ:TNYA Free Report) had its price target lowered by Canaccord Genuity Group from $19.00 to $18.00 in a research note issued to investors on Wednesday, Benzinga...
Share to Feed
HC Wainwright reiterated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA Research Report), Tyra Bioscience (TYRA...
Tenaya Therapeutics (NASDAQ:TNYA Free Report) had its price target lowered by Canaccord Genuity Group from $19.00 to $18.00 in a research report released on Wednesday morning, Benzinga...
Biotech Firm Prepares for Clinical Trials with Extended Cash RunwayRelated Stocks: TNYA...
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA Research Report) and Tenaya Therapeutics...
Investors eyeing a purchase of Tenaya Therapeutics Inc (TNYA) stock, but tentative about paying the going market price of 4.53/share, might benefit from considering selling puts among the...
Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA Get Free Report) have earned a consensus rating of Buy from the seven brokerages that are currently covering the company...
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...